Iron(III)-salophene catalyzes redox cycles that induce phospholipid peroxidation and deplete cancer cells of ferroptosis-protecting cofactors

Su, Fengting; Descher, Hubert; Bui-Hoang, Minh; Stuppner, Hermann; Skvortsova, Ira; Rad, Ehsan Bonyadi; Ascher, Claudia; Weiss, Alexander; Rao, Zhigang; Hohloch, Stephan; Koeberle, Solveigh C.; Gust, Ronald; Koeberle, Andreas

doi:10.1016/j.redox.2024.103257

Redox Biology

2024

DOI: 10.1016/j.redox.2024.103257

|View full text |Cite

Iron(III)-salophene catalyzes redox cycles that induce phospholipid peroxidation and deplete cancer cells of ferroptosis-protecting cofactors

Fengting Su,

Hubert Descher,

Minh Bui-Hoang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Preprint1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A Novel Nanomedicine for Osteosarcoma Treatment: Triggering Ferroptosis through GSH Depletion and Inhibition for Enhanced Synergistic PDT/PTT Therapy

Xu,

Ma,

Zhang

et al. 2024

Preprint

View full text Add to dashboard Cite

Osteosarcoma treatment remains challenging due to the limitations of single-modality therapies.To address this, we designed a carrier-free nanomedicine SRF@CuSO4.5H2O@IR780 (CSIR) for synergistic ferroptosis, photodynamic therapy (PDT), and photothermal therapy (PTT) in osteosarcoma. Interestingly, CSIR could harness the enhanced permeability and retention (EPR) effect to effectively enter tumors. Copper ions (Cu2+) within CSIR could react with the reductive intracellular environment, depleting glutathione (GSH) levels. Near-infrared (NIR) irradiation of CSIR further depleted GSH through reactive oxygen species (ROS) generation. Additionally, CSIR released sorafenib (SRF), which inhibited cystine-glutamate antiporter system xCT (xCT), thereby blocking GSH biosynthesis. RNA sequencing data confirmed ferroptosis induction by CSIR. This synergistic strategy of GSH depletion-induced ferroptosis, enhanced PDT, and photothermal cascade holds promise for improved osteosarcoma treatment and future nanomedicine design.

show abstract

A Novel Nanomedicine for Osteosarcoma Treatment: Triggering Ferroptosis through GSH Depletion and Inhibition for Enhanced Synergistic PDT/PTT Therapy

Xu,

Ma,

Zhang

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Iron(III)-salophene catalyzes redox cycles that induce phospholipid peroxidation and deplete cancer cells of ferroptosis-protecting cofactors

Cited by 1 publication

References 105 publications

A Novel Nanomedicine for Osteosarcoma Treatment: Triggering Ferroptosis through GSH Depletion and Inhibition for Enhanced Synergistic PDT/PTT Therapy

A Novel Nanomedicine for Osteosarcoma Treatment: Triggering Ferroptosis through GSH Depletion and Inhibition for Enhanced Synergistic PDT/PTT Therapy

Contact Info

Product

Resources

About